Supernus Q2 2025: Qelbree +31%, Sage acquisition closed, guidance raised

SUPERNUS PHARMACEUTICALS, INC.

2025-Q2 EPS reported $0.19 revenue$315,277,000

Total revenues Q2 2025: $165.5M vs $168.3M; non-GAAP rev ex-Trokendi/Oxtellar up 17% YoY.
Qelbree net sales $77.6M (+31% YoY); GOCOVRI net sales $36.7M (+16% YoY); 225k IQVIA prescriptions.
Adjusted operating earnings (non-GAAP) $40.9M; operating income $12.1M; raising FY 2025 guidance.
Closed Sage Therapeutics acquisition on July 31, adding ZURZUVAE; ONAPGO launch: 750+ enrollment forms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.